State of Wyoming Buys Shares of 68,678 LifeStance Health Group, Inc. $LFST

State of Wyoming purchased a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 68,678 shares of the company’s stock, valued at approximately $736,000.

A number of other large investors have also recently made changes to their positions in LFST. Silversmith Partners I GP LLC bought a new position in LifeStance Health Group during the fourth quarter valued at approximately $100,842,000. Vanguard Group Inc. grew its position in LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after purchasing an additional 3,086,506 shares during the period. Jennison Associates LLC grew its position in LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after buying an additional 1,839,465 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after buying an additional 1,790,694 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LFST has been the subject of several research analyst reports. BTIG Research lifted their price objective on LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen raised LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Barclays boosted their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings raised shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.12.

Insider Buying and Selling

In related news, COO Lisa K. Miller sold 47,912 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares in the company, valued at approximately $3,051,985.65. The trade was a 14.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CTO Vukasin Paunovich sold 44,394 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at $2,684,789.10. This represents a 15.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 14,629,850 shares of company stock worth $154,952,012 over the last ninety days. 3.50% of the stock is owned by corporate insiders.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $12.42 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The company has a market cap of $4.82 billion, a price-to-earnings ratio of 95.55 and a beta of 1.14. LifeStance Health Group, Inc. has a 1 year low of $4.77 and a 1 year high of $12.76. The firm has a fifty day moving average price of $10.39 and a 200-day moving average price of $8.23.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same period in the previous year, the business earned ($0.01) earnings per share. LifeStance Health Group’s quarterly revenue was up 26.1% compared to the same quarter last year. As a group, equities analysts predict that LifeStance Health Group, Inc. will post 0.15 earnings per share for the current year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.